Moreover, our data show that TAK-242 and IPA-3 are very effective in blocking β-catenin signaling in colon cancer cells challenged by Fn. Therefore, TLR4 and PAK1 could be putative pharmaceutical targets for the treatment of Fn-related CRCs. This evidence concerns the gene FN1 and malignant colon neoplasm.